Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny study asks: do your genes block exercise gains from statins?

NCT ID NCT04636138

Knowledge-focused Sponsor: University of Kansas Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether genetic differences change how well exercise works for people taking statins. Five overweight or obese adults on high-dose atorvastatin will do supervised exercise for 6 weeks. Researchers will measure fitness changes and link them to each person's genes. The goal is to understand why some statin users don't get the same exercise benefits.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

5 people

The number who actually took part.

Started

Jun 2021

Expected to finish

Jul 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

35 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * English-speaking * Adults (aged 35-65 years) * Overweight or obese (body-mass index \[BMI\] 25-43) * Currently taking high-dose atorvastatin (40-80mg once daily) for primary prevention of cardiovascular disease and/or stroke * Sedentary (\<30 minutes of structured exercise weekly) * Willing to participate in supervised exercise three times weekly * Willing to not make intentional changes to their diet during the study period. Exclusion Criteria: * Tobacco smokers * Pregnant or breastfeeding * Use other medications that affect lipid metabolism (e.g. fibric acid, fish oil) * Markedly functional debilitated and unable to exert 4 metabolic equivalents (METs) of energy (e.g. unable to climb a flight of stairs without stopping), or who have * Been advised by a physician to avoid exercise due to comorbid serious cardiovascular disease * Uncontrolled diabetes (A1c \> 8) * Uncontrolled thyroid disease * HIV/AIDS * Cancer * History of myocardial infarction or stroke * History of statin-induced myopathy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HMG-coa reductase inhibitor toxicity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

statin toxicity

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HMG-coa reductase inhibitor toxicity

Contacts and locations

Locations

  • University of Kansas Medical Center

    Kansas City, Kansas, 66160, United States